IW-3300

Ironwood Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	IW-3300
Sponsor	Ironwood Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (PHASE2)
A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects (PHASE1)
A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IW-3300 CI brief — competitive landscape report
IW-3300 updates RSS · CI watch RSS
Ironwood Pharmaceuticals, Inc. portfolio CI